# A Phase III Trial of Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma

> clinical trial · VERIFIED · 2026-07-09

Status: NOT_YET_RECRUITING · Sponsor: Zhejiang Cancer Hospital · Condition: Intrahepatic Cholangiocarcinoma (Icc)

- Company: Zhejiang Cancer Hospital
- Sector: Intrahepatic Cholangiocarcinoma (Icc)
- Primary source: https://clinicaltrials.gov/study/NCT07691515

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.